Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial
Med · 2025-09 · 6 (9) · 100725
DOI: 10.1016/j.medj.2025.100725 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Med, 2025-09. Verfasst von Felix Müller und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Basel, Department of Psychiatry (UPK), 4012 Basel, Switzerland; University Hospital Basel and University of Basel, Division of Clinical…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Lysergic Acid Diethylamide, Psychotherapy, Hallucinogens. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: This trial aimed to assess the efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with moderate-to-severe major depressive disorder. METHODS: This was a randomized, parallel, double-blind, low-dose controlled trial (Clinicaltrials.gov: NCT03866252). Patients were randomly assigned in a 1:1 ratio to receive supportive psychotherapy and either 100 μg + 200 μg LSD or 25 μg + 25 μg LSD in two dosing sessions. The primary endpoints were the changes in scores on the Inventory of Depressive Symptomatology, in the Clinician-Rated (IDS-C) version (assessed by the treating therapist) and the Self-Rated (IDS-SR) version, from baseline to 2 weeks after the second administration. The IDS scores were also assessed 6 and 12 weeks after the second administration. FINDINGS: Thirty-one patients were randomized to the low-dose group, and 30 were randomized to the high-dose group. At the primary endpoint, least-squares mean change (LSM) in IDS-SR scores was -3.9 in the low-dose and -11.8 in the high-dose group (difference: -7.9; 95% CI, -16.0 to 0.3; effect size: -0.5; p = 0.059). LSM in IDS-C scores was -3.6 in the low-dose and -12.9 in the high-dose group (difference: -9.2; CI, -17.1 to -1.3; effect size: -0.6; p = 0.023; corrected
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Basel, Department of Psychiatry (UPK), 4012 Basel, Switzerland; University Hospital Basel and University of Basel, Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department…
- University of Basel, Department of Psychiatry (UPK), 4012 Basel, Switzerland.
- University Hospital Basel and University of Basel, Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, 4031 Basel, Switzerland.
- Department of Psychiatry and Psychotherapy, University of Lübeck, 23538 Lübeck, Germany.
- University of Basel, Department of Psychiatry (UPK), 4012 Basel, Switzerland; University Hospital Basel, Department of Palliative Care, 4031 Basel, Switzerland.
Zitieren
APA
Müller, F., Zaczek, H., Becker, A. M., Ley, L., Borgwardt, S., Santos de Jesus, J., Loh, N., Kohut, J., Auernig, M., Boehlke, C., & Liechti, M. E. (2025). Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. Med, 6(9), 100725. https://doi.org/10.1016/j.medj.2025.100725
Vancouver
Müller F, Zaczek H, Becker AM, Ley L, Borgwardt S, Santos de Jesus J, et al. Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. Med. 2025;6(9):100725. doi:10.1016/j.medj.2025.100725
BibTeX
@article{Mller2025,
author = {Müller, Felix and Zaczek, Hannes and Becker, Anna M and Ley, Laura and Borgwardt, Stefan and Santos de Jesus, Joyce and Loh, Nico and Kohut, Jan and Auernig, Mathias and Boehlke, Christopher and Liechti, Matthias E},
title = {Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial},
journal = {Med},
year = {2025},
volume = {6},
number = {9},
pages = {100725},
doi = {10.1016/j.medj.2025.100725}
}
EUVIMED